Steigerwald Gordon & Koch Inc. Buys 1,994 Shares of Johnson & Johnson $JNJ

Key Points

• Steigerwald Gordon & Koch Inc. has increased its stake in Johnson & Johnson by 1.8%, acquiring 1,994 additional shares, bringing its total to 114,347 shares valued at approximately $17.47 million.
• Various large investors, including Elios Financial Group and Atlantic Family Wealth, have recently adjusted their stakes in Johnson & Johnson, highlighting growing institutional interest in the company.
• Analysts are optimistic about Johnson & Johnson's future performance, raising price targets to as high as $200, while the stock has an average rating of "Moderate Buy" with a current price target of $181.40.

Steigerwald Gordon & Koch Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 114,347 shares of the company's stock after acquiring an additional 1,994 shares during the period. Johnson & Johnson comprises about 1.8% of Steigerwald Gordon & Koch Inc.'s portfolio, making the stock its 24th largest position. Steigerwald Gordon & Koch Inc.'s holdings in Johnson & Johnson were worth $17,467,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in the company. Elios Financial Group Inc. boosted its position in shares of Johnson & Johnson by 1.5% during the first quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock worth $746,000 after buying an additional 66 shares during the period. Atlantic Family Wealth LLC lifted its stake in Johnson & Johnson by 4.4% in the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock valued at $266,000 after acquiring an additional 67 shares in the last quarter. MBA Advisors LLC boosted its position in Johnson & Johnson by 1.2% during the 1st quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after acquiring an additional 68 shares during the last quarter. Sovereign Financial Group Inc. grew its stake in shares of Johnson & Johnson by 1.8% during the 1st quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock worth $651,000 after acquiring an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc lifted its position in shares of Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after purchasing an additional 69 shares in the last quarter. Institutional investors own 69.55% of the company's stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on JNJ shares. Royal Bank Of Canada lifted their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. JPMorgan Chase & Co. lifted their target price on Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a research report on Tuesday, September 16th. Morgan Stanley increased their price target on Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Bank of America raised their price target on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research note on Thursday, July 17th. Finally, Barclays upped their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average price target of $181.40.

Johnson & Johnson Stock Performance

JNJ opened at $176.35 on Wednesday. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $181.16. The business has a 50 day moving average of $173.56 and a 200-day moving average of $161.79. The stock has a market cap of $424.71 billion, a price-to-earnings ratio of 18.86, a PEG ratio of 2.22 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter in the prior year, the business earned $2.82 EPS. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson's payout ratio is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.